Elizabeth Evans

Chief Operating Officer

Vaccinex (United States)

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Elizabeth Evans is the Chief Operating Officer at Vaccinex in the United States. Her research primarily focuses on the role of semaphorin 4D in neurodegenerative diseases, particularly Huntington’s disease, and its implications in neuroinflammation and cancer. She has contributed significantly to clinical studies involving Pepinemab, emphasizing its potential in treating advanced non-small cell lung cancer and its interaction with immune cells.

Articles (5)

Year:

2024

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (1)

Brad A. Racette

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Elizabeth Evans

Research Interests

Explore related searches

Contact this professor

About

Articles (5)

Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial

Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial

Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity

A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer

Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy

Collaborators (1)

Brad A. Racette

Make your next move.